. Author manuscript; available in PMC: 2016 Mar 11.

Published in final edited form as: Cancer Chemother Pharmacol. 2008 Apr 15;63(3):441–450. doi: 10.1007/s00280-008-0754-2

Table 3.

Treatment-related non-hematologic and hematologic toxicity in Cycle 1 (worst grade per patient)

Dose level	Ox (mg/m²)	Irino (mg/m²)	Cape mg bid	No. of Pts	Non-hematologic Toxicity and grade
					Diarrhea				Nausea				Vomiting				Neurosensory				Anorexia				Fatigue
					1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
1A	60	40	1,000	4	0	1	2	0	2	1	1	0	2	1	1	0	3	0	0	0	3	0	0	0	1	1	0	0
1	60	40	300	3	2	0	0	0	3	0	0	0	1	0	0	0	2	0	0	0	2	0	0	0	3	0	0	0
2	60	40	450	6	4	0	0	0	2	0	0	0	2	0	0	0	6	0	0	0	1	0	0	0	3	1	0	0
3	60	50	450	6	2	0	2	0	2	0	2	0	0	1	2	0	2	0	0	0	3	0	0	0	0	3	0	0
4	60	60	450	3	0	0	3	0	1	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	1	2	0	0

Dose level	Ox (mg/m²)	Irino (mg/m²)	Cape mg bid	No. of Pts	Hematologic toxicity and grade
					Hemoglobin				Leukopenia				Neutropenia				Platelets
					1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
1A	60	40	1,000	4	2	2	0	0	1	0	1	0	0	0	0	1	1	0	1	0
1	60	40	300	3	3	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0
2	60	40	450	6	3	2	1	0	3	1	0	0	0	1	1	0	2	0	0	0
3	60	50	450	6	4	2	0	0	3	2	1	0	0	0	3	0	2	0	0	0
4	60	60	450	3	2	1	0	0	1	0	2	0	0	0	1	1	1	0	0	0

Ox oxaliplatin, Irino irinotecan, Cape capecitabine, Pts patients